Abstract
It is well established that the immunosuppressive effects of cyclosporin A (CsA) and FK506 (also known as tacrolimus) are mediated through binding to their cognate cellular proteins cyclophilin and FKBP (collectively termed immunophilins), respectively. Biochemical analysis had revealed that cyclophilin-CsA and FKBP-FK506 complexes bind to and inactivate Ca2+- dependent serine / threonine phosphatase calcineurin. Since calcineurin regulates nuclear translocation and subsequent activation of nuclear factor of activated T cells (NFAT) transcription factors that is one of essential steps for cytokine gene expression in activated T cells, it is believed that inhibition of calcineurin is a molecular basis of the immunosuppressive properties of CsA and FK506. However, recent studies indicate that both CsA and FK506 can block activation of JNK and p38 signaling pathways during T cell activation. CsA and FK506, thus, have two distinct mechanisms of action; one is the inhibition of the protein phosphatase activity of calcineurin, leading to the blockade of the nuclear translocation of NFAT transcription factors, and the other is the suppression of JNK and p38 activation pathways. It is likely that the presence of two distinct targets in T cell activation makes CsA and FK506 highly potent immunosuppressive drugs. Here we discuss the action of immunophilin-ligand complexes on JNK and p38 activation pathways. We also argue the possibility of immunotherapeutic application targeting at JNK and p38 signaling pathways.
Keywords: mapk signaling pathways, immunophilin-ligand complex, immunosuppressive effects, cognate cellular proteins, fkbp-fk506 complexes, nuclear factor of activated T cells, immunosuppressive drugs, p38 signaling pathways
Current Topics in Medicinal Chemistry
Title: Regulation of MAPK Signaling Pathways Through Immunophilin-ligand Complex
Volume: 3 Issue: 12
Author(s): Satoshi Matsuda and Shigeo Koyasu
Affiliation:
Keywords: mapk signaling pathways, immunophilin-ligand complex, immunosuppressive effects, cognate cellular proteins, fkbp-fk506 complexes, nuclear factor of activated T cells, immunosuppressive drugs, p38 signaling pathways
Abstract: It is well established that the immunosuppressive effects of cyclosporin A (CsA) and FK506 (also known as tacrolimus) are mediated through binding to their cognate cellular proteins cyclophilin and FKBP (collectively termed immunophilins), respectively. Biochemical analysis had revealed that cyclophilin-CsA and FKBP-FK506 complexes bind to and inactivate Ca2+- dependent serine / threonine phosphatase calcineurin. Since calcineurin regulates nuclear translocation and subsequent activation of nuclear factor of activated T cells (NFAT) transcription factors that is one of essential steps for cytokine gene expression in activated T cells, it is believed that inhibition of calcineurin is a molecular basis of the immunosuppressive properties of CsA and FK506. However, recent studies indicate that both CsA and FK506 can block activation of JNK and p38 signaling pathways during T cell activation. CsA and FK506, thus, have two distinct mechanisms of action; one is the inhibition of the protein phosphatase activity of calcineurin, leading to the blockade of the nuclear translocation of NFAT transcription factors, and the other is the suppression of JNK and p38 activation pathways. It is likely that the presence of two distinct targets in T cell activation makes CsA and FK506 highly potent immunosuppressive drugs. Here we discuss the action of immunophilin-ligand complexes on JNK and p38 activation pathways. We also argue the possibility of immunotherapeutic application targeting at JNK and p38 signaling pathways.
Export Options
About this article
Cite this article as:
Matsuda Satoshi and Koyasu Shigeo, Regulation of MAPK Signaling Pathways Through Immunophilin-ligand Complex, Current Topics in Medicinal Chemistry 2003; 3 (12) . https://dx.doi.org/10.2174/1568026033451916
DOI https://dx.doi.org/10.2174/1568026033451916 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Can Statin be a Novel Pharmacophore for Antidiabetic Activity?
Mini-Reviews in Medicinal Chemistry Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Essential Structural and Functional Features of Small Heat Shock Proteins in Molecular Chaperoning Process
Protein & Peptide Letters Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?
Current Medicinal Chemistry Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology Commentary: Participation of Sox-1 Expression and Signaling of β-Catenin in the Pathophysiology of Generalized Seizures in Cerebellum of Rat
CNS & Neurological Disorders - Drug Targets Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Genetic Engineering in Allotransplantation of Vascularized Organs
Current Gene Therapy Benefit of SERCA2a Gene Transfer to Vascular Endothelial and Smooth Muscle Cells: A New Aspect in Therapy of Cardiovascular Diseases
Current Vascular Pharmacology The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Editorial [Hot Topic: From Structural Plasticity to Functional Diversity of 7TMRs: Biased Agonism and Beyond (Executive Guest Editor: Christodoulos S. Flordellis)]
Current Pharmaceutical Design